Analysis of Tau-441 protein in clinical samples using rGO/AuNP nanocomposite-supported disposable impedimetric neuro-biosensing platform: Towards Alzheimer's disease detection

Karaboğa, Münteha Nur Sonuç; Sezgintürk, Mustafa Kemal

doi:10.1016/j.talanta.2020.121257

Cited by 36 publications

(19 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The engineered tau-441 analytic immunosensor target demonstrated a linear response within a concentration range of 1-500 pg/mL and a detection limit of 0.091 pg/mL. The study's encouraging argument is that in this neurobiosensor, both serum fluid and cerebrospinal fluid (CSF) samples with recovery rates ranging from 96 to 108 percent can catch tau-441 target proteins [90]. For the S100ß protein, a biomarker of Alzheimer's disease found in brain astrocytes, a sandwich-type photoelectrochemical immunoassay was identified.…”

Section: Gold Nanoparticles Effects On Amyloid Beta Peptidementioning

confidence: 95%

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients

Abbas

2021

Polymers

View full text Add to dashboard Cite

The disorder of Alzheimer’s is marked by progressive pathophysiological neurodegeneration. The amino acid peptides in the amyloid plaques found in the brains of people with Alzheimer’s disease (AD) are known as amyloid-beta (Aβ). Current treatments are not curative, and the effects associated with AD are reduced. Improving treatment results involved the targeting of drugs at optimum therapeutic concentration. Nanotechnology is seen as an unconventional, modern technology that plays a key role in the treatment of Alzheimer’s disease. Using nanoparticles, molecular detection, effective drug targeting, and their combination offer high sensitivity. The aim of this review is to shed light on the function and successful role of nanoparticles to resolve Aβ aggregation and thus to help cure Alzheimer’s disease. The analysis divides these nanoparticles into three categories: polymer, lipid, and gold nanoparticles. A thorough comparison was then made between the nanoparticles, which are used according to their role, properties, and size in the procedure. The nanoparticles can prevent the accumulation of Aβ during the efficient delivery of the drug to the cells to treat Alzheimer’s disease. Furthermore, this comparison demonstrated the ability of these nanoparticles to deal efficiently with Alzheimer’s disease. The role of these nanoparticles varied from delivering the drug to brain cells to dealing with the disease-causing peptide.

show abstract

Section: Gold Nanoparticles Effects On Amyloid Beta Peptidementioning

confidence: 95%

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients

Abbas

2021

Polymers

View full text Add to dashboard Cite

show abstract

“…Based on the antioxidant and anti-inflammatory characters, AuNP exposure can relieve the brain damage in the AD model (Kaushik et al, 2019). AuNPs in combination with reduced graphene or coated with anti-tau antibodies can act as neuro-probes and detect the Tau-441 target proteins both in serum fluid and cerebrospinal fluid (Neely et al, 2009;Karaboga and Sezgintürk, 2020). AuNPs conjugated with Co 2+ can be used to investigate the Aβ peptides' aggregation kinetics and their self-assembly stages in MRI images (Sparks, 2008).…”

Section: Gold (Au) Npsmentioning

confidence: 99%

Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

Khan

Mir

Ngowi

et al. 2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a devastating disease of the aging population characterized by the progressive and slow brain decay due to the formation of extracellular plaques in the hippocampus. AD cells encompass tangles of twisted strands of aggregated microtubule binding proteins surrounded by plaques. Delivering corresponding drugs in the brain to deal with these clinical pathologies, we face a naturally built strong, protective barrier between circulating blood and brain cells called the blood–brain barrier (BBB). Nanomedicines provide state-of-the-art alternative approaches to overcome the challenges in drug transport across the BBB. The current review presents the advances in the roles of nanomedicines in both the diagnosis and treatment of AD. We intend to provide an overview of how nanotechnology has revolutionized the approaches used to manage AD and highlight the current key bottlenecks and future perspective in this field. Furthermore, the emerging nanomedicines for managing brain diseases like AD could promote the booming growth of research and their clinical availability.

show abstract

“…A significant reduction in neuronal cells was observed that rescued destruction of memory cells in AD affected rats (Chen et al, 2018). Karaboga et al (2020) developed nanocomposite biosensor comprising of reduced graphene oxide and gold nanoparticles. The surface of nanocomposite was functionalized with 11-mercaptoundeconoic acid to target tau-441 protein accountable for degeneration of memory cells.…”

Section: Nanocompositesmentioning

confidence: 99%

Nanocarriers for Alzheimer’s disease: Research and patent update

Pathak¹,

Kiran²,

Porwal³

et al. 2021

J Appl Pharm Sci

View full text Add to dashboard Cite

Alzheimer's disease (AD) is one of the most progressive neurodegenerative disorders resulting in cognitive and behavioral impairment in individuals beyond 65 years of age. It is distinguished by deposits of extracellular amyloidal protein intracellular and neurofibrillary tangles resulting in senile plaques. Significant advancement has been made in AD therapeutics; however, most of the treatment approaches are based on attenuating symptoms, implying that AD is still an insolvable neurodegenerative illness. Though an enormous number of drug moieties were already screened for different molecular targets of AD, only few of them (N-methyl D-aspartate receptor antagonists and acetylcholinesterase inhibitors) are currently implied for efficacious clinical treatment. Though these medications slow down the development of the disorder and give symptomatic relief; yet they are unsuccessful in achieving a proven cure. Nonetheless, targeted drug delivery of these medications to the Central nervous system (CNS) manifested various restrictions like meager solubility, lower bioavailability along with diminished effectiveness because of the bloodbrain barrier. Recent developments in nanotechnology present chances to overcome such limitations in targeting. Various nanocarriers have been researched that offer promising targeting capabilities. This review aims to provide an update on various dosage forms based on nanotechnology aimed for AD therapeutics, the patents on nanocarriers for AD and clinical trials on AD drugs.

show abstract

Analysis of Tau-441 protein in clinical samples using rGO/AuNP nanocomposite-supported disposable impedimetric neuro-biosensing platform: Towards Alzheimer's disease detection

Cited by 36 publications

References 46 publications

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients

Nanomedicine: A Promising Way to Manage Alzheimer’s Disease

Nanocarriers for Alzheimer’s disease: Research and patent update

Contact Info

Product

Resources

About